Take a look at how Abzena’s ThioBridge® conjugation overcomes issues with existing technologies to give you antibody-drug conjugate (ADCs) with improved stability, potency, and efficacy.

What’s Inside?

While ADCs are a powerful and targeted approach to therapeutics, first-generation conjugation technologies have limitations such as inconsistent drug-to-antibody ratios (DAR) and the risk of early payload detachment. Abzena’s ThioBridge® conjugation technology offers a solution by providing a more uniform DAR profile, stable linker attachment, and improved pharmacokinetic properties.